Skip to content

Gornet et al. Allogeneic disc progenitor cells for lumbar disc degeneration

One-paragraph summary

Sixty adults with symptomatic single-level lumbar degeneration were randomized at 13 US sites to low-dose cells (20), high-dose cells (20), vehicle (10) or placebo (10). At 52 weeks, high-dose VAS fell 62.8% from baseline and by 42.8 points; benefit persisted at 104 weeks. Only high-dose treatment significantly increased disc volume: +249.0 mm³ at week 52 and +402.1 mm³ at week 104 (both p=0.028). Severe adverse events occurred in 18.3%; serious events in 6.7%, all in vehicle/placebo and judged unrelated (PMID 38925869).

Key findings

  • 60 participants, mean age 37.9 years; 60% men.
  • Randomized, double-blind, four-arm design at 13 sites.
  • High-dose VAS change −62.8% at week 52.
  • High-dose absolute VAS change −42.8 points.
  • Disc volume +249.0 mm³ at 52 weeks and +402.1 mm³ at 104 weeks.
  • Clinical and structural effects were dose-specific.

Limitations

  • Small groups and multiple comparisons.
  • Vehicle itself had a significant VAS decline.
  • Product-specific findings cannot be generalized to all cells.
  • Two years is short for tumor, ectopic tissue and durability surveillance.
  • Sponsor and regulatory context require independent replication.
  • Disc-volume change is not a validated surrogate for mechanics or function.

Why it matters

This trial provides one of the clearest paired structural and clinical signals for intradiscal cell therapy. It raises the standard for subsequent studies: standardized product, blinded control, dose response and long-term safety rather than uncontrolled “stem-cell” claims.

Cited by wiki pages

  • Overview
  • Regenerative and biologic therapy
  • Outcomes and measurement
  • Guidelines
  • Clinical trials landscape